Press Releases :: Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

May 24, 2022

Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity

May 23, 2022

Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference

May 10, 2022

Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

May 3, 2022

Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022

Apr 4, 2022

Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

Mar 23, 2022

Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Mar 18, 2022

Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022

Mar 17, 2022

Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea

Mar 9, 2022

Journey Medical Corporation to Present at the 34th Annual ROTH Conference

Feb 11, 2022

QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation

rss_feed News RSS